Capturing outcomes of clinical activities performed by a rounding pharmacist practicing in a team environment: The COLLABORATE study [NCT00351676]

Medical Care

Volumn 47, Issue 6, 2009, Pages 642-650

  Makowsky, Mark J ^a   Koshman, Sheri L ^a   Midodzi, William K ^a   Tsuyuki, Ross T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Family medicine; Internal medicine; Patient care team; Pharmacists; Quality indicators

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PHARMACY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG USE; EVIDENCE BASED MEDICINE; FAMILY MEDICINE; FEMALE; HEALTH CARE QUALITY; HEART FAILURE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INTERNAL MEDICINE; MAJOR CLINICAL STUDY; MALE; MEDICAL ERROR; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PATIENT COUNSELING; PHARMACIST; RISK ASSESSMENT; TEAMWORK; CHRONIC DISEASE; GENERAL PRACTICE; HEALTH SERVICES RESEARCH; HOSPITAL PHARMACY; PATIENT CARE; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; TEACHING HOSPITAL; TREATMENT OUTCOME;

AGED; CHRONIC DISEASE; FAMILY PRACTICE; FEMALE; GUIDELINE ADHERENCE; HEALTH SERVICES RESEARCH; HOSPITALS, TEACHING; HUMANS; MALE; PATIENT CARE TEAM; PHARMACY SERVICE, HOSPITAL; PRACTICE GUIDELINES AS TOPIC; QUALITY OF HEALTH CARE; TREATMENT OUTCOME;

EID: 67449103478     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181926032     Document Type: Article

References (48)

1. Leape LL, Cullen DJ, Clapp MD, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999;282:267-270.
2. Kucukarslan SN, Peters M, Mlynarek M, et al. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003;163:2014-2018.
3. Bussieres JF. Clinical pharmacy services. In: Johnson N, Hall KW, Wilgosh C, et al, eds. Hosptial Pharmacy in Canada: Ethics in Hospital Pharmacy. 2007. Available at: http://www.lillyhopstialsurvey.ca. Accessed August 21, 2007.
4. Holland R, Lenaghan E, Harvey I, et al. Does home based medication review keep older people out of hospital? The HOMER randomised controlled trial. BMJ. 2005;330:293.
5. Holland R, Brooksby I, Lenaghan E, et al. Effectiveness of visits from community pharmacists for patients with heart failure: HeartMed randomized controlled trial. BMJ. 2007;334:1098.
6. Holland R, Desborough J, Goodyer L, et al. Does pharmacist-led medication review help to reduce hospital admissions and deaths in older people? A systematic review and meta-analysis. Br J Clin Pharmacol. 2008;65:303-316.
7. Van Wijk BL, Klungel OH, Heerdink ER, et al. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother. 2005;39: 319-328.
8. O'Dell KM, Kucukarslan SN. Impact of the clinical pharmacist on readmission in patients with acute coronary syndrome. Ann Pharmacother. 2005;39:1423-1427.
9. Royal S, Smeaton L, Avery AJ, et al. Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis. Qual Saf Health Care. 2006;15:23.
10. Salter C, Holland R, Harvey I, et al. "I haven't even phoned my doctor yet." The advice giving role of the pharmacist during consultations for medication review with patients aged 80 or more: qualitative discourse analysis. BMJ. 2007;334:1101.
11. Dranitsaris G, Spizzirri D, Pitre M, et al. A randomized trial to measure the optimal role of the pharmacist in promoting evidence-based antibiotic use in acute care hospitals. Int J Technol Assess Health Care. 2001;17:171-180.
12. Hanlon JT, Weinberger M, Samsa GP, et al. A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996; 100:428-437.
13. Gattis WA, Hasselblad V, Whellan DJ, et al. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159:1939-1945.
14. Tsuyuki RT, Johnson JA, Teo KK, et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med. 2002;162:1149-1155.
15. Ellis SL, Carter BL, Malone DC, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20:1508-1516.
16. Morrison A, Wertheimer AI. Evaluation of studies investigating the effectiveness of pharmacists' clinical services. Am J Health Syst Pharm. 2001;58:569-577.
17. Pickard AS, Johnson JA, Farris KB. The impact of pharmacist interventions on health-related quality of life. Ann Pharmacother. 1999;33: 1167-1172.
18. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy. 1999;19:556-564.
19. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and hospital mortality rates. Pharmacotherapy. 2007;27:481.
20. Bond CA, Raehl CL, Franke T. Interrelationships among mortality rates, drug costs, total cost of care, and length of stay in United States hospitals: summary and recommendations for clinical pharmacy services and staffing. Pharmacotherapy. 2001;21:129-141.
21. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, pharmacy staffing, and the total cost of care in United States hospitals. Pharmacotherapy. 2000;20:609-621.
22. Schumock GT, Butler MG, Meek PD, et al. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy. 2003;23:113-132.
23. Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002;22:134-147.
24. Bond CA, Raehl CL. Clinical pharmacy services, pharmacy staffing, and adverse drug reactions in United States hospitals. Pharmacotherapy. 2006;26:735-747.
25. Kaboli PJ, Hoth AB, McClimon BJ, et al. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;166:955-964.
26. Bond CA, Raehl CL, Patry R. Evidence-based core clinical pharmacy services in United States hospitals in 2020: services and staffing. Pharmacotherapy. 2004;24:427-440.
27. Smith WE. Role of a pharmacist in improving rational drug therapy as part of the patient care team. Ann Pharmacother. 2007;41:330-335.
28. Majumdar SR, Rowe BH, Folk D, et al. A controlled trial to increase detection and treatment of osteoporosis in older patients with a wrist fracture. Ann Intern Med. 2004;141:366-373.
29. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-543.
30. Asch SM, McGlynn EA, Hogan MM, et al. Comparison of quality of care for patients in the Veterans Health Administration and patients in a national sample. Ann Intern Med. 2004;141:938-945.
31. Kahn SR, Panju A, Geerts W, et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119:145-155.
32. Patel K, Loewen P, Wilbur K. A retrospective evaluation of adherence to guidelines for prevention of thromboembolic events in general medical patients. Can J Hosp Pharm. 2006;59:258-263.
33. Aujesky D, Guignard E, Pannatier A, et al. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med. 2002;17:788-791.
34. Stark JE, Kilzer WJ. Venous thromboembolic prophylaxis in hospitalized medical patients. Ann Pharmacother. 2004;38:36-40.
35. Rahim SA, Panju A, Pai M, et al. Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review. Thromb Res. 2003; 111:215-219.
36. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox. JAMA. 2004;291: 1864-1870.
37. Alter DA, Manuel DG, Gunraj N, et al. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. Am J Med. 2004;116: 540-545.
38. Lee DS, Tu JV, Juurlink DN, et al. Risk-treatment mismatch in the pharmacotherapy of heart failure. JAMA. 2005;294:1240-1247.
39. Lee DS, Tran C, Flintoft V, et al. CCORT/CCS quality indicators for congestive heart failure care. Can J Cardiol. 2003;19:357-364.
40. American College of Cardiology AHA, Physician Consortium for Performance Improvement,. Clinical performance measures. Chronic stable coronary artery disease. 2003. Available at: http://www.ama-assn.org. Accessed January 21, 2005.
41. Centres for Medicare and Medicade Services (CMS). Seventh statement of work (SOW). Quality of care measure specifications: Pneumonia (PNE) 2002.
42. Choi PP, Day A, Etchells E. Gaps in the care of patients admitted to hospital with an exacerbation of chronic obstructive pulmonary disease. CMAJ. 2004;170:1409-1413.
43. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:338S-400S.
44. Samama MM, Cohen AT, Darmon JY, et al. Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
45. Rhew DC, Goetz MB, Shekelle PG. Evaluating quality indicators for patients with community-acquired pneumonia. Jt Comm J Qual Improv. 2001;27:575-590.
46. Joint Commission on Accreditation of Healthcare Organizations (JCAHO). Specifications Manual for National Hospital Quality Measures. 2005. Available at: http://www.jointcommission.org. Accessed January 21, 2005.
47. O'Donnell DE, Aaron S, Bourbeau J, et al. State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J. 2004;11(suppl B):7B-59B.
48. National Diabetes Quality Improvement Alliance. National Diabetes Quality Improvement Alliance performance measurement set for adult diabetes 2005. Available at: http://www.nationaldiabetesalliance.org. Accessed January 21, 2005.